Rising cases of accidental nicotine exposure in children prompt an FDA warning and safety call to manufacturers.

In the CRL response letter, Capricor noted that the FDA’s call to reject deramiocel was “difficult to understand” and ...

Commenters to the FDA also advocated for safety reforms and for industry funds to be used for post-market monitoring.